Novelion

NVLN-T

0.00
0.00 (0.00%)
This company is not ACTIVE.

Analysis and Opinions about NVLN-T

Signal
Opinion
Expert
BUY WEAKNESS
BUY WEAKNESS
August 7, 2009
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 7, 2009
(Market Call Minute.) Could see it as a Buy but would like it at a cheaper price.
SELL
SELL
October 23, 2007
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
Show full opinionHide full opinion
Novelion (NVLN-T)
October 23, 2007
The future isn't bright. Losing market share with their main product. Suggests tax loss selling.
DON'T BUY
DON'T BUY
December 22, 2005
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 22, 2005
Has been a very disappointing stock. Had problems with its major drug because of competition. The problem with the Canadian drug sector is that it tends to be one or two drug dependent.
SELL
SELL
November 11, 2005
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 11, 2005
The biggest threat to any business is a competing technology or product. That's what the market thinks is happening here.
DON'T BUY
DON'T BUY
September 29, 2005
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 29, 2005
The drug companys are due for a slow turn around. Had a lot of problems with the FDA. Lots of competition going to happen.
DON'T BUY
DON'T BUY
August 11, 2005
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 11, 2005
Looks cheap at 10 X earnings. Have a drug that is photo-activated, but competitors have come which has pulled the stock down. Bought a company that had an acne cream, but because of labeling problems, it's another year or two away.
WAIT
WAIT
June 15, 2005
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 15, 2005
Likes the company from the standpoint of a product. Thinks they are still way ahead of the competitors, particularily in the eye treatment area. Have expanded their product base which is not bad. Market has been unmerciful to this stock. Hopefully it has hit a bottom, but would wait to see if the stock can work its way through.
DON'T BUY
DON'T BUY
June 6, 2005
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 6, 2005
A one trick pony. Visudine is great, but they haven't really gone beyond this. Getting new competition.
SELL
SELL
May 25, 2005
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
Show full opinionHide full opinion
Novelion (NVLN-T)
May 25, 2005
Their treatment of macular degeneration only treats the latter stage while the competition is going after the initial stage. This company is like a one trick pony. Major competition is coming in.
DON'T BUY
DON'T BUY
April 11, 2005
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
Show full opinionHide full opinion
Novelion (NVLN-T)
April 11, 2005
This is bottom fishing, bargain hunting on a stock that is below the 200 day moving average. This stock is really base building. The stock is not participating in this bull market, so will possibly sit out the next bear market and you may have to wait for the next bull market which could be 2 years away.
DON'T BUY
DON'T BUY
March 10, 2005
Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
Show full opinionHide full opinion
Novelion (NVLN-T)
March 10, 2005
Perhaps should sell... recovery could be 6,8,9 months down the road. Could be dead money.
WEAK BUY
WEAK BUY
March 9, 2005
Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
Show full opinionHide full opinion
Novelion (NVLN-T)
March 9, 2005
Sold his holdings last year and hasn't come back to it yet, but is watching closely. Visudyne now has growing competition. Didn't like the Attrix acquisition and not sure if they will get any growth from it. Has good cash position, assets and core product.
DON'T BUY
DON'T BUY
February 15, 2005
You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
Show full opinionHide full opinion
Novelion (NVLN-T)
February 15, 2005
You have to wait to see some strength come back in the pharmaceuticals. They were formerly a one drug company, but with their recent acquisition, it makes them a little bit more interesting, but there is still no buying going on.
DON'T BUY
DON'T BUY
February 14, 2005
Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
Show full opinionHide full opinion
Novelion (NVLN-T)
February 14, 2005
Visudyne has done really well but competition is coming from Pfizer. Will lose a little bit of market share for awhile and growth will slow down. In the end they may win the battle, but in the short term it will be difficult. Not happy with the recent merger with Atrix Laboritories. Felt they had a weak pipeline.
WAIT
WAIT
February 1, 2005
Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
Show full opinionHide full opinion
Novelion (NVLN-T)
February 1, 2005
Because of the acquisition they just did, would like to see a couple of quarters of results out of the new drugs that are in that acquisition. Has seen some weakness with a 10/15% decline in sales.
BUY
BUY
January 17, 2005
Closed their merger in December, so hopefully the share price indigestion that comes with mergers is over. Fundamentally not expensive, Chart is interesting. Balance sheet is in good shape. His holdings is on a paired/trade situation with a short on Eyetech (EYET-Q). Very beaten up stock, but has some decent prospects.
Show full opinionHide full opinion
Novelion (NVLN-T)
January 17, 2005
Closed their merger in December, so hopefully the share price indigestion that comes with mergers is over. Fundamentally not expensive, Chart is interesting. Balance sheet is in good shape. His holdings is on a paired/trade situation with a short on Eyetech (EYET-Q). Very beaten up stock, but has some decent prospects.
BUY
BUY
January 7, 2005
Strong balance sheet. Outlook for the sale of their product is quite encouraging.
Show full opinionHide full opinion
Novelion (NVLN-T)
January 7, 2005
Strong balance sheet. Outlook for the sale of their product is quite encouraging.
DON'T BUY
DON'T BUY
December 23, 2004
Has had a disappointing year. Some competitive drugs have been approved by the FDA which will attack part of its market share. Growth profile for the next couple of years is not that strong.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 23, 2004
Has had a disappointing year. Some competitive drugs have been approved by the FDA which will attack part of its market share. Growth profile for the next couple of years is not that strong.
BUY
BUY
December 17, 2004
Recently made an intelligent acquisition that diversified the product base. Market didn't see it that way, but over time, it should strengthen the price of QLT.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 17, 2004
Recently made an intelligent acquisition that diversified the product base. Market didn't see it that way, but over time, it should strengthen the price of QLT.
DON'T BUY
DON'T BUY
December 1, 2004
Dropped below the 200 day moving average.
Show full opinionHide full opinion
Novelion (NVLN-T)
December 1, 2004
Dropped below the 200 day moving average.
VAGUE
VAGUE
November 25, 2004
Facing some competition which is worrisome. In the smaller end of the ocular market and would prefer companies in the other end.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 25, 2004
Facing some competition which is worrisome. In the smaller end of the ocular market and would prefer companies in the other end.
DON'T BUY
DON'T BUY
November 11, 2004
Not too bullish on the stock, but wouldn't necessarily sell it if you own. Their key drug Visudine is facing some competition. Upside could be limited in the short term.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 11, 2004
Not too bullish on the stock, but wouldn't necessarily sell it if you own. Their key drug Visudine is facing some competition. Upside could be limited in the short term.
TOP PICK
TOP PICK
November 9, 2004
Their Visudine product is a leader with the highest market share in the last few months. Their prostate cancer product will be significant. Attractive valuation. Has cash.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 9, 2004
Their Visudine product is a leader with the highest market share in the last few months. Their prostate cancer product will be significant. Attractive valuation. Has cash.
BUY
BUY
November 8, 2004
Has not been a big winner over the last year, but thinks it's going to do pretty well. Likes its product.
Show full opinionHide full opinion
Novelion (NVLN-T)
November 8, 2004
Has not been a big winner over the last year, but thinks it's going to do pretty well. Likes its product.
DON'T BUY
DON'T BUY
October 20, 2004
Has a great product for dealing with macular degeneration but has had some very disappointing clinical results. Increasing competition in their product. Too expensive.
Show full opinionHide full opinion
Novelion (NVLN-T)
October 20, 2004
Has a great product for dealing with macular degeneration but has had some very disappointing clinical results. Increasing competition in their product. Too expensive.
WEAK BUY
WEAK BUY
September 17, 2004
Competition has a product that has more application for macular degeneration. A little bit of a gamble, but is certainly a popular application.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 17, 2004
Competition has a product that has more application for macular degeneration. A little bit of a gamble, but is certainly a popular application.
DON'T BUY
DON'T BUY
September 16, 2004
Not a contrarian stock. Still in the sexy kind of biotech miracle cure stage. Got way ahead of itself. Have a lot of egss in one basket which makes them vulnerable. A lot of competition. Needs to be cheaper and more product diversification.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 16, 2004
Not a contrarian stock. Still in the sexy kind of biotech miracle cure stage. Got way ahead of itself. Have a lot of egss in one basket which makes them vulnerable. A lot of competition. Needs to be cheaper and more product diversification.
DON'T BUY
DON'T BUY
September 14, 2004
Vrey volatile. In the health care sector, would look more to the US, such as Johnson & Johnson.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 14, 2004
Vrey volatile. In the health care sector, would look more to the US, such as Johnson & Johnson.
DON'T BUY
DON'T BUY
September 8, 2004
Revenues and earnings are doing pretty well. Trades at about 18 X earnings. A lot of cash. Involved in a questionable acquisition in the US. Some competition. We'll continue to stall in the foreseeable future.
Show full opinionHide full opinion
Novelion (NVLN-T)
September 8, 2004
Revenues and earnings are doing pretty well. Trades at about 18 X earnings. A lot of cash. Involved in a questionable acquisition in the US. Some competition. We'll continue to stall in the foreseeable future.
VAGUE
VAGUE
August 26, 2004
More competitions coming in. It is a great business. At this level, the stock is reasonably attractive. However, up and downs for this stock is limited.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 26, 2004
More competitions coming in. It is a great business. At this level, the stock is reasonably attractive. However, up and downs for this stock is limited.
WEAK BUY
WEAK BUY
August 26, 2004
Would buy the stocks. They would recommand people to look at this stock. However, this stock has been going up and down.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 26, 2004
Would buy the stocks. They would recommand people to look at this stock. However, this stock has been going up and down.
BUY WEAKNESS
BUY WEAKNESS
August 23, 2004
At an interesting entry point. A competitor of theirs is in front of the FDA for approval of a competing drug for Visudine. This may create some weakness, but not a problem as there's plenty of room for both players.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 23, 2004
At an interesting entry point. A competitor of theirs is in front of the FDA for approval of a competing drug for Visudine. This may create some weakness, but not a problem as there's plenty of room for both players.
HOLD
HOLD
August 17, 2004
The jury is out on this stock. Made a major acquisition and the market hasn't liked it very much. Would want to wait for one or two quarters before buying.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 17, 2004
The jury is out on this stock. Made a major acquisition and the market hasn't liked it very much. Would want to wait for one or two quarters before buying.
HOLD
HOLD
August 3, 2004
The numbers have been a little slow on this company. There's always great expectations for biotech companies. Sales are coming in at a steady pace.
Show full opinionHide full opinion
Novelion (NVLN-T)
August 3, 2004
The numbers have been a little slow on this company. There's always great expectations for biotech companies. Sales are coming in at a steady pace.
DON'T BUY
DON'T BUY
July 30, 2004
The biotech area in Canada is a tough area to be in. A one trick pony. Has a fantastic drug for macular degenerative eye disorder. Some competition is coming out for them, possibly in the next few weeks.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 30, 2004
The biotech area in Canada is a tough area to be in. A one trick pony. Has a fantastic drug for macular degenerative eye disorder. Some competition is coming out for them, possibly in the next few weeks.
BUY
BUY
July 22, 2004
Has dropped after the acquisition. Real cheap now.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 22, 2004
Has dropped after the acquisition. Real cheap now.
DON'T BUY
DON'T BUY
July 14, 2004
Stock just broke below its 200 day moving average. That's a negative sign.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 14, 2004
Stock just broke below its 200 day moving average. That's a negative sign.
DON'T BUY
DON'T BUY
July 7, 2004
Atrix was a big acquisition for a company this size. They want to broaden their product line and this acquisition will give them more opportunity, but not sure if they can handle the size of this.
Show full opinionHide full opinion
Novelion (NVLN-T)
July 7, 2004
Atrix was a big acquisition for a company this size. They want to broaden their product line and this acquisition will give them more opportunity, but not sure if they can handle the size of this.
DON'T BUY
DON'T BUY
June 30, 2004
Just did an acquisition. At this level, the stock is fairly valued. Has moved from being a biotech play to a specialty pharma.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 30, 2004
Just did an acquisition. At this level, the stock is fairly valued. Has moved from being a biotech play to a specialty pharma.
HOLD
HOLD
June 17, 2004
Acquiring Atrix which is expensive, but transforms them into a multi-product company. Probably won't know if it works until 2006.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 17, 2004
Acquiring Atrix which is expensive, but transforms them into a multi-product company. Probably won't know if it works until 2006.
HOLD
HOLD
June 14, 2004
Market didn't like news. Wait.
Show full opinionHide full opinion
Novelion (NVLN-T)
June 14, 2004
Market didn't like news. Wait.